Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis
Open Access
- 1 August 2001
- journal article
- Published by Elsevier BV in The Annals of Thoracic Surgery
- Vol. 72 (2), 371-379
- https://doi.org/10.1016/s0003-4975(01)02787-4
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Sequence-dependent enhancement of paclitaxel toxicity in non–small cell lung cancer by 17-allylamino 17-demethoxygeldanamycinThe Journal of Thoracic and Cardiovascular Surgery, 1999
- Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cellsOncogene, 1998
- Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lungThe Annals of Thoracic Surgery, 1998
- The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycinCancer Chemotherapy and Pharmacology, 1998
- Depletion of p185 erbB2 , Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activityCancer Chemotherapy and Pharmacology, 1997
- Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissueBritish Journal of Cancer, 1997
- Enhanced Chemoresistance by Elevation of p185neu Levels in HER-2/neu-Transfected Human Lung Cancer CellsJNCI Journal of the National Cancer Institute, 1995
- Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell lineBritish Journal of Cancer, 1995
- Preclinical pharmacologic evaluation of geldanamycin as an antitumor agentCancer Chemotherapy and Pharmacology, 1995
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987